Lykke Pedersen, PhD.

Lykke is Abzu's Chief Pharma Officer and an expert in RNA therapeutics.

Abzu

Lykke's legacy: Transforming RNA therapeutics and AI.

Exploring the future of RNA therapeutics with Lykke.

Welcome to the world of Lykke Pedersen, a visionary in the realm of RNA therapeutics and a key figure at Abzu. With a deep passion for innovation and a clear vision for the future, Lykke’s work embodies the cutting-edge of drug design and AI in RNA therapeutics.

An infinite number of lead candidates does not mean an infinite number of drugs, let alone good drugs.
Lykke Pedersen, Chief Pharma Officer at Abzu, considers the benefits of explainable AI and its applications within the pharma industry.
OTS is a forum to foster academic and industry-based research and development of oligonucleotide therapeutics.
Investigating the next generation of genetic medicine through RNA-based therapies.
OTS is a forum to foster academic and industry-based research and development of oligonucleotide therapeutics.
Sharing the latest trends, innovations, and best practices for digitizing R&D assets to accelerate modern science.

About Lykke Pedersen, PhD:

Chief Pharma Officer.

Lykke was awarded her PhD in Biophysics from the University of Copenhagen and conducted research at the Niels Bohr Institute. Although her education is in Physics, she’s a Bioinformatician at heart and has over 9 years’ experience working in the pharmaceutical industry, specifically RNA therapeutics.

Lykke is skilled in machine learning, mathematical modeling, statistics, and gene expression profiling, and she is an expert in R programming.

Lykke Pedersen, Head of RNA Therapeutics

Lykke Pedersen outside of Abzu’s office in Copenhagen, Denmark.

Subscribe for
notifications from Abzu.

You can opt out at any time. We’re cookieless, and our privacy policy is actually easy to read.